ad

Asymptomatic Alzheimer’s Disease Anti-Amyloid Trial

The purpose of this study is to test whether an investigational drug called solanezumab can slow the progression of memory problems associated with brain amyloid (the protein that forms plaques in the brains of people with Alzheimer’s disease) as compared with placebo in subjects with preclinical AD.

Summary

  • Study director: Adam Boxer, MD, PhD
  • Sponsor: Eli Lilly & Company and National Institute on Aging (NIA)
  • Recruiting?: Yes
  • Official study title: Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4 Study)
  • ClinicalTrials.gov identifier: NCT02008357

Daniel Schonhaut

Research Coordinator

Daniel Schonhaut is a research associate with Dr. Rabinovici and works on amyloid imaging projects.

Publications

A selection of the abstracts and manuscripts published using EXAMINER data.

The publications listed on this page are a selection of the articles published that used the EXAMINER battery. If you wish to look for more, you can search PubMED, which is maintained by the National Library of Medicine, or Google Scholar.

Manuscripts

  1. Kramer, J.H. (2014). Special Series Introduction: NIH EXAMINER and the Assessment of Executive Functioning. Journal of the International Psychological Society, 20(1), 8-10. doi: 10.1017/S1355617713001185

Panos Theofilas, PhD

Postdoctoral Scholar

Panos Theofilas joined the Grinberg lab at the UCSF Memory and Aging Center in 2012. His research focuses on the neuropathological changes and susceptibility of subcortical brain regions in the earliest stages of Alzheimer's disease. Dr. Theofilas’ methodology includes analyses of human brain circuitries as a whole by combining unbiased stereology, immunohistochemistry/biochemical assays, and 3D computer graphics for histological brain volume reconstructions. His academic background includes a BSc degree in zoology and an MSc degree in neuroscience from the University of Edinburgh, UK. He completed his PhD degree at Bonn University in Germany on programmed cell death signaling pathways in animal models of temporal lobe epilepsy.

Alzheimer’s Disease Trial of Levetiracetam

The purpose of this study is to evaluate whether the anti-epileptic drug levetiracetam reduces subclinical (clinically silent) epileptiform activity and improves cognition in people with Alzheimer’s disease. Epileptiform activity is a term used to describe the abnormal firing of neurons in ways similar to epilepsy or seizure disorder.

Summary

  • Study director: Keith Vossel, MD, MSc
  • Sponsor: Alzheimer’s Association, Inc.; NIH National Institute on Aging; S.D. Bechtel, Jr. Foundation
  • Recruiting?: Yes
  • Official study title: A Phase 2A Levetiracetam Trial for Alzheimer’s Disease—Associated Network Hyperexcitability

Frequently Asked Questions (FAQ)

Read through our list of commonly asked questions about using the NIH EXAMINER Test Battery.


General

Q: Are there norms for each individual subtest or just the composite scores? We are hoping to get age- or age-and-education-based norms.

Alzheimer’s Disease Trial with TPI-287

Tau is a microtubule-associated protein, and abnormal tau function has been proposed to play a role in the development and progression of Alzheimer’s disease (AD). TPI-287 is an stabilizer of microtubule dynamics, and the stabilization of microtubules is hypothesized to compensate for the loss of tau function in AD. The purpose of this study is to determine the dose of TPI-287 that is safe and tolerable in people with mild to moderate AD, as well as to measure the properties and preliminary efficacy of TPI-287.

Summary

  • Study director: Adam Boxer, MD, PhD
  • Sponsor: UCSF (Funder: Alzheimer’s Association)
  • Recruiting?: Yes
  • Official study title: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TPI-287 in Patients with Mild to Moderate Alzheimer’s Disease

Alzheimer’s Disease Trial of Solanezumab

The production and deposition of amyloid plaques in the brain is thought to contribute to the development and progression of Alzheimer’s disease (AD). Solanezumab is hypothesized to reduce accumulation of amyloid plaques and thus slow the progression of AD. The primary purpose of the study is to determine if solanezumab will slow cognitive and functional decline in participants with mild AD.

Summary

  • Study director: Adam Boxer, MD, PhD
  • Sponsor: Eli Lilly & Company
  • Recruiting?: Not recruiting
  • Official study title: Effect of Passive Immunization on the Progression of Mild Alzheimer’s Disease: Solanezumab (LY2062430) Versus Placebo
  • ClinicalTrials.gov identifier: NCT01900665
  • Conditions studied: Mild Alzheimer's disease

Anesthesia

The risk of cognitive decline related to surgery and anesthesia continues to be debated in the scientific literature. Some animal studies suggest that anesthesia may worsen the development of the plaques and tangles associated with Alzheimer’s disease while others identify the surgical procedure itself to be a problem by causing inflammation and release of harmful proteins. Others attribute temporary or permanent cognitive changes to the medications used to manage pain or other complications of being hospitalized. Ultimately, although this is a very active area of research, there are no definitive studies in older humans that prove a causative effect on the brain from anesthesia or provide recommendations on specific choices of anesthesia. Despite this, we hope to be able to identify information that may help our patients with cognitive problems evaluate the risk and make informed choices about surgery and anesthesia.

The risk of cognitive decline related to surgery and anesthesia continues to be debated in the scientific literature. Some animal studies suggest that anesthesia may worsen the development of the plaques and tangles associated with Alzheimer’s disease while others identify the surgical procedure itself to be a problem by causing inflammation and release of harmful proteins. Others attribute temporary or permanent cognitive changes to the medications used to manage pain or other complications of being hospitalized.

Syndicate content